ArticleApplied microbiology and biotechnology2014
Recombinant Aspergillus β-galactosidases as a robust glycomic and biotechnological tool.
Article in Applied microbiology and biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Preparation of novel karaya gum derived covalent immobilizers via polyethylene-imine and glutaraldehyde processing.Scientific reports · 2026Article
- Insights into the Lignocellulose-Degrading Enzyme System Based on the Genome Sequence ofInternational journal of molecular sciences · 2025Article
- Recombinant production of Paenibacillus wynnii β-galactosidase with Komagataella phaffii.Microbial cell factories · 2024Article
- Analysis of Caenorhabditis Protein Glycosylation.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Influence of Oligosaccharides when Measuring Lactose and Total Carbohydrates in Human Milk and Comparison of Methods.The Journal of nutrition · 2023Article
- Increasing Complexity of the N-Glycome During Caenorhabditis Development.Molecular & cellular proteomics : MCP · 2023Article
- Molecular Cloning and Characterization of a Novel Exo-β-1,3-Galactanase fromJournal of microbiology and biotechnology · 2022Article
- Strategies Shaping the Transcription of Carbohydrate-Active Enzyme Genes inJournal of fungi (Basel, Switzerland) · 2022Article
- Enzymatic degradation of xyloglucans by Aspergillus species: a comparative view of this genus.Applied microbiology and biotechnology · 2021Review
- A statistical approach for enhanced production of β-galactosidase from Paracoccus sp. and synthesis of galacto-oligosaccharides.Folia microbiologica · 2020Article
- Sulfated and sialylatedThe Journal of biological chemistry · 2020Article
- Ablation of N-acetylglucosaminyltransferases in Caenorhabditis induces expression of unusual intersected and bisected N-glycans.Biochimica et biophysica acta. General subjects · 2018Article
- The parasitic nematode Oesophagostomum dentatum synthesizes unusual glycosaminoglycan-like O-glycans.Glycobiology · 2018Article
- Core Richness of N-Glycans of Caenorhabditis elegans: A Case Study on Chemical and Enzymatic Release.Analytical chemistry · 2018Article
- Systematic assessment ofSynthetic and systems biotechnology · 2017Article
- Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells.Scientific reports · 2017Article
- Gender and developmental specific N-glycomes of the porcine parasite Oesophagostomum dentatum.Biochimica et biophysica acta. General subjects · 2017Article
- Analysis of Invertebrate and Protist N-Glycans.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Analysis of zwitterionic and anionic N-linked glycans from invertebrates and protists by mass spectrometry.Glycoconjugate journal · 2016Review
- Multistep Fractionation and Mass Spectrometry Reveal Zwitterionic and Anionic Modifications of the N- and O-glycans of a Marine Snail.Molecular & cellular proteomics : MCP · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Galactosidases are widespread enzymes that are used for manifold applications, including production of prebiotics, biosynthesis of different transgalactosylated products, improving lactose tolerance and in various analytical approaches. The nature of these applications often require galactosidases to be present in a purified form with clearly defined properties, including precisely determined substrate specificities, low sensitivity to inhibitors, and high efficiency and stability under distinct conditions. In this study, we present the recombinant expression and purification of two previously uncharacterized β-galactosidases from Aspergillus nidulans as well as one β-galactosidase from Aspergillus niger. All enzymes were active toward p-nitrophenyl-β-D-galactopyranoside as substrate and displayed similar temperature and pH optima. The purified recombinant galactosidases digested various complex substrates containing terminal galactose β-1,4 linked to either N-acetylglucosamine or fucose, such as N-glycans derived from bovine fibrin and Caenorhabditis elegans. In our comparative study of the recombinant galactosidases with the commercially available galactosidase from Aspergillus oryzae, all enzymes also displayed various degrees of activity toward complex oligosaccharides containing β-1,3-linked terminal galactose residues. All recombinant enzymes were found to be robust in the presence of various organic solvents, temperature variations, and freeze/thaw cycles and were also tested for their ability to synthesize galactooligosaccharides. Furthermore, the use of fermentors considerably increased the yield of recombinant galactosidases. Taken together, we demonstrate that purified recombinant galactosidases from A. niger and from A. nidulans are suitable for various glycobiological and biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.